EUVIMEDEUVIMED entdecken
Crossref

The Safety of Biologic Treatment for Asthma in Pregnancy

Madeline S Kellam, Jeffrey M Chambliss, Luyu Xie, Timothy G Chow

The Journal of Allergy and Clinical Immunology: In Practice · 2026

DOI: 10.1016/j.jaip.2026.01.035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026. Verfasst von Madeline S Kellam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Immunology, Departments of Internal Medicine and Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas. …. Hauptthemen laut MEDLINE: Asthma, Pregnancy Complications, Anti-Asthmatic Agents, Biological Products.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Poorly controlled asthma during pregnancy has been associated with adverse maternal and neonatal outcomes. Biologic medications, such as mAbs, can improve control and reduce exacerbations in patients with moderate to severe asthma. However, there is limited data about the safety of biologics during pregnancy. OBJECTIVE: To determine the frequency of adverse pregnancy outcomes in patients with moderate to severe persistent asthma prescribed biologic therapies compared with an unexposed disease-matched cohort. METHODS: This is a retrospective cohort study using the TriNetX US Collaborative Network. Pregnant women aged 15 to 44 years with moderate to severe asthma between January 2010 and July 2025 were identified. The study included 2 groups, the asthma biologic prescription group and unexposed asthma controls, which were 1:1 propensity score-matched by age, race, ethnicity, comorbidities, substance use, and obesity. Primary outcomes were defined as maternal and fetal complications that occurred in relation to the index event (pregnancy date). Odds ratios with 95% CIs were calculated between matched groups for each outcome. RESULTS: After propensity score matching, there were 535 pregnant patients in each group. There was a decreased risk of any adverse pregnancy outcome in the asthma biologic prescription group when compared with the disease-matched control group (odds ratio, 0.609; 95% CI, 0.460-0.807; P = .001). CONCLUSIONS: Prescribed biologics for the treatment of moderate to severe asthma during pregnancy were not associated with an increased risk for adverse pregnancy outcomes when compared with disease-matched controls, and may have a protective effect in reducing adverse pregnancy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaPregnancy ComplicationsAnti-Asthmatic AgentsBiological ProductsHumansFemalePregnancyAdultRetrospective StudiesAdolescentPregnancy OutcomeYoung Adult

Stichwörter der Autor:innen

AsthmaBiologicsOutcomesPregnancySafety

Substanzen

Anti-Asthmatic AgentsBiological Products

Autor:innen und Institutionen

  • Division of Allergy and Immunology, Departments of Internal Medicine and Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: madeline.kellam@utsouthwestern.edu.
  • Division of Allergy and Immunology, Departments of Internal Medicine and Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Quantitative Biomedical Research Center, Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas.

Zitieren

APA

Kellam, M. S., Chambliss, J. M., Xie, L., & Chow, T. G. (2026). The Safety of Biologic Treatment for Asthma in Pregnancy. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2026.01.035

Vancouver

Kellam MS, Chambliss JM, Xie L, Chow TG. The Safety of Biologic Treatment for Asthma in Pregnancy. The Journal of Allergy and Clinical Immunology: In Practice. 2026. doi:10.1016/j.jaip.2026.01.035

BibTeX
@article{Kellam2026,
  author = {Kellam, Madeline S and Chambliss, Jeffrey M and Xie, Luyu and Chow, Timothy G},
  title = {The Safety of Biologic Treatment for Asthma in Pregnancy},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2026},
  doi = {10.1016/j.jaip.2026.01.035}
}
Kostenlos starten →